Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/31401

Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study

Título :
Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study
Autor :
Barrachina, Jordi
Margarit, Cesar
Muriel, Javier  
López‑Gil, Santiago
López Gil, Vicente  
Vara-González, Amaya  
Planelles, Beatriz
Inda, María del Mar
Morales, Domingo
Peiró, Ana María
Editor :
Nature Portfolio
Departamento:
Departamentos de la UMH::Farmacología, Pediatría y Química Orgánica
Fecha de publicación:
2022
URI :
https://hdl.handle.net/11000/31401
Resumen :
Tapentadol (TAP) and oxycodone/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness and security in daily pain practice, together with the influence of pharmacogenetic markers. An observational study was developed with ambulatory test cases under TAP (n = 194) or OXN (n = 175) prescription with controls (prescribed with other opioids (control), n = 216) CNCP patients. Pain intensity and relief, quality of life, morphine equivalent daily doses (MEDD), concomitant analgesic drugs, adverse events (AEs), hospital frequentation and genetic variants of OPRM1 (rs1799971, A118G) and COMT (rs4680, G472A) genes, were analysed. Test CNCP cases evidenced a significantly higher pain relief predictable due to pain intensity and quality of life (R2 = 0.3), in front of controls. Here, OXN achieved the greatest pain relief under a 28% higher MEDD, 8-13% higher use of pregabalin and duloxetine, and 23% more prescription change due to pain, compared to TAP. Whilst, TAP yielded a better tolerability due the lower number of 4 [0-6] AEs/patient, in front of OXN. Furthermore, OXN COMT-AA homozygotes evidenced higher rates of erythema and vomiting, especially in females. CNCP real-world patients achieved higher pain relief than other traditional opioids with a better tolerability for TAP. Further research is necessary to clarify the potential influence of COMT and sex on OXN side-effects.
Tipo documento :
application/pdf
Derechos de acceso:
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
DOI :
https://doi.org/10.1038/s41598-022-13085-5
Aparece en las colecciones:
Artículos Farmacología, Pediatría y Química Orgánica



Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.